Latest Industry Insights

Bio-Rad's Jeremiah McDole explores the benefits of bringing molecular testing in-house and how ddPCR technology can be applied in oncology workflows.

In this interview, James Brayer delves into some of the current obstacles hindering the widespread adoption of genomic medicine and highlights how nanopore-based sequencing can help to address them.

Technology Networks spoke to Dr. Ofer Sharon, CEO of OncoHost, to learn about the challenges in non-small cell lung cancer treatment and how proteomics-based analysis could enable personalized cancer treatments.

In this interview, Dr. Tabitha Bullock tells us about some of the key considerations in cell line development and how advances in technology are improving the efficiency and productivity of cell lines.

A new method to biofortify pea shoots with vitamin B12 could tackle deficiency issues. In this interview with Technology Networks, Professor Antony Dodd, head of cell and developmental biology at the John Innes Centre, explains why.

Sustainability is an important area of focus for modern laboratory operations. In this article, Tarun Anumol, PhD, Global Environment Market Director at Agilent Technologies discusses sustainability in environmental testing labs.

In this interview, Technology Networks spoke to Heiko Neuweger, director of Bioinformatics Life Science Mass Spectrometry Software R&D at Bruker, to learn about the importance of target compound annotation and identification, the advantages of integrating collision cross section (CCS) information into workflows and the benefits of CCS-Predict Pro.

In this interview, Dr. Lorna De Leoz, global food segment director at Agilent Technologies, highlights practical advice to make a food and beverage lab more sustainable. She also discusses the role of metrics when establishing sustainability goals and how vendors can work with labs to ensure they achieve these goals.

This article looks at the technologies currently being developed that can help to identify patients with a higher risk of prostate cancer, ultimately reducing the number of unnecessary biopsies.

Andrew Schulman explores why we need allogeneic therapies, the importance of collaboration to keep the momentum, and challenges and predictions for the future.